Altered Hippocampal and Striatal Expression of Endothelial Markers and VIP/PACAP Neuropeptides in a Mouse Model of Systemic Lupus Erythematosus
暂无分享,去创建一个
G. Musumeci | M. Mandwie | G. Logan | A. Castorina | Jayden Lee | Sarah Thomas Broome | R. Marzagalli | M. I. Jansen | Rubina Marzagalli
[1] J. Hannibal,et al. Localization of the neuropeptides pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study , 2022, Frontiers in Neuroanatomy.
[2] Erik W Anderson,et al. Cognitive dysfunction in SLE: An understudied clinical manifestation. , 2022, Journal of autoimmunity.
[3] Qian Wang,et al. Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus , 2022, Journal of clinical medicine.
[4] F. Napolitano,et al. Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications , 2022, International journal of molecular sciences.
[5] A. Swarnkar,et al. Striatal dominant lupus encephalitis–Is it vasculitis or an autoimmune process? Literature review & new case report with vessel wall imaging , 2022, Radiology case reports.
[6] A. Castorina,et al. Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides. , 2022, Journal of integrative neuroscience.
[7] K. Keay,et al. Metformin Treatment Attenuates Brain Inflammation and Rescues PACAP/VIP Neuropeptide Alterations in Mice Fed a High-Fat Diet , 2021, International journal of molecular sciences.
[8] C. Putterman,et al. TWEAKing the Hippocampus: The Effects of TWEAK on the Genomic Fabric of the Hippocampus in a Neuropsychiatric Lupus Mouse Model , 2021, Genes.
[9] W. Brinjikji,et al. Striatal Encephalitis: Potential Inflammatory Vasculopathy in Systemic Lupus Erythematosus , 2020, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[10] Shanshan Liu,et al. Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study , 2020, Modern rheumatology.
[11] Justin G. Roy,et al. Reliable reference genes for the quantification of mRNA in human T-cells and PBMCs stimulated with live influenza virus , 2020, BMC Immunology.
[12] Chih-Ming Lin,et al. A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review , 2019, Neurology international.
[13] Yi Zhu,et al. BDNF-mediated mitophagy alleviates high-glucose-induced brain microvascular endothelial cell injury , 2019, Apoptosis.
[14] K. Keay,et al. PACAP and VIP expression in the periaqueductal grey of the rat following sciatic nerve constriction injury , 2019, Neuropeptides.
[15] C. Putterman,et al. Neuropsychiatric lupus: new mechanistic insights and future treatment directions , 2019, Nature Reviews Rheumatology.
[16] B. Griffith,et al. Neuropsychiatric Lupus with Antibody-Mediated Striatal Encephalitis , 2018, American Journal of Neuroradiology.
[17] Y. Joo,et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study , 2018, Lupus.
[18] T. Hirabayashi,et al. Discovery of PACAP and its receptors in the brain , 2018, The Journal of Headache and Pain.
[19] M. R. Kim,et al. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer , 2018, International journal of molecular sciences.
[20] R. Jenkins,et al. Markers and Biomarkers of Endothelium: When Something Is Rotten in the State , 2017, Oxidative medicine and cellular longevity.
[21] Di Lian,et al. Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis , 2017, Journal of Neuroinflammation.
[22] V. Yang,et al. Krüppel-like factor 4 (KLF4): What we currently know. , 2017, Gene.
[23] H. Jo,et al. KLF2 and KLF4 control endothelial identity and vascular integrity. , 2017, JCI insight.
[24] Lingyun Sun,et al. Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort , 2016, PloS one.
[25] E. Kowalczyk,et al. Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors , 2016, Neurochemical Research.
[26] P. Garnier,et al. Brain BDNF levels are dependent on cerebrovascular endothelium‐derived nitric oxide , 2016, The European journal of neuroscience.
[27] A. Clarke,et al. The global burden of SLE: prevalence, health disparities and socioeconomic impact , 2016, Nature Reviews Rheumatology.
[28] W. Luo,et al. Role of vasoactive intestinal peptide in osteoarthritis , 2016, Journal of Biomedical Science.
[29] P. Jayaraman,et al. Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression* , 2016, The Journal of Biological Chemistry.
[30] R. Schmidt-Kastner,et al. Genomic approach to selective vulnerability of the hippocampus in brain ischemia–hypoxia , 2015, Neuroscience.
[31] A. Rodriguez-Mateos,et al. Central role of eNOS in the maintenance of endothelial homeostasis. , 2015, Antioxidants & redox signaling.
[32] J. Waschek,et al. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses , 2015, Brain, Behavior, and Immunity.
[33] D. Ganea,et al. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases , 2015, Acta physiologica.
[34] S. Small,et al. Isolating Pathogenic Mechanisms Embedded within the Hippocampal Circuit through Regional Vulnerability , 2014, Neuron.
[35] M. Chopp,et al. Subacute Intranasal Administration of Tissue Plasminogen Activator Promotes Neuroplasticity and Improves Functional Recovery following Traumatic Brain Injury in Rats , 2014, PloS one.
[36] Ling Lin,et al. Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms. , 2014, American journal of clinical and experimental immunology.
[37] Shi-ting Li,et al. Endothelial Nitric Oxide Synthase Protects Neurons against Ischemic Injury through Regulation of Brain‐Derived Neurotrophic Factor Expression , 2014, CNS neuroscience & therapeutics.
[38] S. Cessie,et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE) , 2014, Lupus.
[39] S. Scuderi,et al. Dopamine D3 receptor deletion increases tissue plasminogen activator (tPA) activity in prefrontal cortex and hippocampus , 2013, Neuroscience.
[40] Abdullah M. Khamis,et al. Regional differences in gene expression and promoter usage in aged human brains , 2013, Neurobiology of Aging.
[41] H. Ueda,et al. Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: Implications in the development of neuropathic pain , 2013, Neuroscience.
[42] S. Bilbo,et al. Chemokines and the hippocampus: A new perspective on hippocampal plasticity and vulnerability , 2013, Brain, Behavior, and Immunity.
[43] B. Tzang,et al. Cystamine ameliorates ventricular hypertrophy associated with modulation of IL-6-mediated signaling in lupus-prone mice. , 2013, Life sciences.
[44] Gai-feng Feng,et al. Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro , 2013, Peptides.
[45] R. Carare,et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid‐β from the mouse brain , 2013, Aging cell.
[46] M. Mao,et al. The neuroprotective roles of BDNF in hypoxic ischemic brain injury. , 2013, Biomedical reports.
[47] C. Qualls,et al. Circulating microparticles in neuropsychiatric systemic lupus erythematosus , 2013, International journal of rheumatic diseases.
[48] C. Putterman,et al. Neuropsychiatric Symptoms in Lupus. , 2012, Psychiatric annals.
[49] U. Förstermann,et al. Nitric oxide synthases: regulation and function. , 2012, European heart journal.
[50] Olga Hilas,et al. Lupus: an overview of the disease and management options. , 2012, P & T : a peer-reviewed journal for formulary management.
[51] F. Drago,et al. Dopamine-₃ receptor modulates intraocular pressure: implications for glaucoma. , 2012, Biochemical pharmacology.
[52] A. Popescu,et al. Neuropsychiatric Systemic Lupus Erythematosus , 2011, Current neuropharmacology.
[53] V. Cardile,et al. Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells , 2010, Peptides.
[54] B. Hart,et al. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. , 2010, Seminars in arthritis and rheumatism.
[55] E. Muscal,et al. Neurologic manifestations of systemic lupus erythematosus in children and adults. , 2010, Neurologic clinics.
[56] H. Vaudry,et al. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery , 2009, Pharmacological Reviews.
[57] R. Eisenberg. Why can't we find a new treatment for SLE? , 2009, Journal of autoimmunity.
[58] M. Lisanti,et al. ICAM-1: role in inflammation and in the regulation of vascular permeability. , 2008, American journal of physiology. Heart and circulatory physiology.
[59] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.
[60] Petti T. Pang,et al. Cleavage of proBDNF by tPA/Plasmin Is Essential for Long-Term Hippocampal Plasticity , 2004, Science.
[61] A. Bobik,et al. Metalloproteinases and plasminogen activators in vessel remodeling , 2003, Current hypertension reports.
[62] C. Lau,et al. Pathogenesis of systemic lupus erythematosus , 2003, Journal of clinical pathology.
[63] P. Rieckmann,et al. Human cerebral endothelial cells are a potential source for bioactive BDNF. , 2002, Cytokine.
[64] M. Delgado,et al. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[65] R. Schmidt-Kastner,et al. Selective vulnerability of the hippocampus in brain ischemia , 1991, Neuroscience.
[66] M. van Buchem,et al. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement , 2017, Rheumatology.
[67] Kyuhyung Kim,et al. Neuropeptides. , 2008, WormBook : the online review of C. elegans biology.
[68] P. Cieślik,et al. Vasculopathy and vasculitis in systemic lupus erythematosus. , 2008, Polskie Archiwum Medycyny Wewnetrznej.
[69] M. Delgado,et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases , 2001, Journal of Molecular Medicine.